Skip to content
etf.net

Launched

iShares Neuroscience and Healthcare ETF

IBRNNYSE ArcaiSharesC

$32.44−0.40 (−1.22%)

As of Nov 2, 2026, 2:51 PM ET

C43/ 100

Rank 10 of 17 in Biotech & Genomics

C43/100Rank 10 of 17inBiotech & Genomics
Intraday session: down, 65 prints from 32.84 to 32.44. Range 32.38 to 33.03. Use the arrow keys to read each point.32.6032.7033.0010 AM12 PM2 PM4 PM
Expense ratio
0.47%
Fund size
$7M
1Y total return
+11.2%
Yield · Last 12 months
0.96%
Holdings
71
Avg volume · 30D
2.68K sh
52W range
low $27.70high $43.01
Launched

The ETF.net IBRN Grade

Based on 5 of 6 pillars

C

Score 43 out of 100

Category
Biotech & Genomics⁠
Rank
10 of 17
Six-pillar profile for IBRN. Scores out of 100: Cost 56, Risk 28, Mission not scored, Tradability 25, Holdings 65, Durability 31. Strongest: Holdings (65). Weakest: Tradability (25). Based on 5 of 6 pillars.

Score 43 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    B56 out of 100
    Rank 7 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D28 out of 100
    Rank 13 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D25 out of 100
    Rank 14 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B65 out of 100
    Rank 8 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    D31 out of 100
    Rank 15 of 17

Our read on IBRN

ETF.net Research

In short

CA healthcare fund with one obsession: the brain. IBRN tracks a global index of roughly 70 drugmakers and device companies working on neurological disease, a slice most sector funds bury inside hundreds of names.

Stated mandate

The fund seeks to track an index of global companies advancing research and treatment of neurological disorders, providing focused exposure to healthcare innovation related to brain health.

Why people hold it

  • A rare single-theme cut of healthcare: brain-disease biopharma and medical devices held together, sourced globally rather than US-only.ishares.com
  • At 0.47%, it undercuts the median expense ratio of its broad healthcare peer group, unusual for a narrow theme fund.
  • Rules-based, not a stock picker: it follows a published NYSE FactSet neuro index, so the exposure you own is defined in advance.ishares.com

Worth knowing

  • Small asset base and thin trading. Spreads can run wider than on the sector's heavyweights, and that cost lands on the buyer.
  • 0.47% is several times what plain broad healthcare index funds like VHT and XLV charge. The theme is what you're paying for.
  • Roughly 70 names in one research niche, live since 2022. Trial results at a few companies can swing it more than a whole-sector fund.

IBRN Performance

Launched Aug 24, 2022

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.
IBRN$11,124
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. IBRN $11,124. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for IBRN. Periods over one year show the average yearly return.
PeriodIBRN
Year to date+3.0%
1 month+0.1%
3 months−9.0%
1 year+11.2%
3 yearsper year+20.4%
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for IBRN
YearReturn barIBRN
2026 YTD+3.0%
2025+28.5%
2024−2.8%
2023+0.9%
2022+5.8%

History from Aug 26, 2022

IBRN in the news

IBRN Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.96%Last 12 months
Payout per share
$0.32Last 12 months
Last payment
$0.32 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2023–2026

One bar per payment. 4 payments from 2023 to 2026 YTD. Jun 7, 2023 $0.0082; Dec 20, 2023 $0.0063; Dec 17, 2024 $0.10; Dec 16, 2025 $0.32. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 16, 2025Dec 19, 2025$0.32
Dec 17, 2024Dec 20, 2024$0.10
Dec 20, 2023Dec 27, 2023$0.0063
Jun 7, 2023Jun 13, 2023$0.0082

$10,000 in IBRN 3 years ago paid $205 in dividends.

IBRN Risk

Risk pillarD28 out of 100Rank 13 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
23.6%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.71
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−35.4%
50 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.87
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

IBRN Cost

Compare IBRN and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$5,466

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • IBRN 0.47%

    $9,418

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • IBRN 0.47%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530IBRN $9,418IBBQ $3,952

Year by year

YearIBRNIBBQOverpaying
10$847$347$500
20$3,261$1,351$1,910
30$9,418$3,952$5,466

Other funds in Biotech & Genomics

See others